

A-Engrossed
House Bill 4105

Ordered by the House February 9
Including House Amendments dated February 9

Sponsored by Representative NOSSE (Presession filed.)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure.

Requires pharmacy or pharmacist that dispenses biological product to *[report]* **communicate** certain information electronically or to prescribing practitioner. Provides exceptions.

Sunset January 2, 2022.

Declares emergency, effective on passage.

A BILL FOR AN ACT

1
2 Relating to biological products; creating new provisions; amending ORS 689.522; and declaring an
3 emergency.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1.** ORS 689.522 is amended to read:

6 689.522. *[(1) As used in this section:]*

7 *[(a) "Biological product" means, with respect to the prevention, treatment or cure of a disease or*
8 *condition of human beings, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood compo-*
9 *nent, blood derivative, allergenic product, protein other than a chemically synthesized polypeptide,*
10 *analogous products or arsphenamine or any other trivalent organic arsenic compound.]*

11 *[(b) "Biosimilar product" means a biological product licensed by the United States Food and Drug*
12 *Administration pursuant to 42 U.S.C. 262(k)(3)(A)(i).]*

13 *[(c) "Interchangeable" means, in reference to a biological product, that the United States Food and*
14 *Drug Administration has determined that a biosimilar product meets the safety standards set forth in*
15 *42 U.S.C. 262(k)(4).]*

16 *[(d) "Reference biological product" means the biological product licensed pursuant to 42 U.S.C.*
17 *262(a) against which a biological product is evaluated in an application submitted to the United States*
18 *Food and Drug Administration for licensure of a biological product as a biosimilar product or for*
19 *determination that a biosimilar product is interchangeable.]*

20 *[(2)]* **(1)** A pharmacy or pharmacist filling a prescription order for a biological product may not
21 substitute a *[biosimilar]* **biological** product for the prescribed biological product unless:

22 (a) The *[biosimilar]* **substitute biological** product has been determined by the United States
23 Food and Drug Administration to be interchangeable with the prescribed biological product;

24 (b) The prescribing practitioner has not designated on the prescription that substitution is pro-
25 hibited;

26 (c) The patient for whom the biological product is prescribed is informed of the substitution
27 *[prior to dispensing the biosimilar product]* **in a manner reasonable under the circumstances;** and

NOTE: Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted.
New sections are in **boldfaced** type.

1 (d) The pharmacy or pharmacist retains a record of the substitution for a period of not less than
2 three years.

3 (2) Not later than five business days after the dispensing of a biological product, the
4 pharmacy or pharmacist, or the pharmacist's designee, shall communicate the specific bi-
5 ological product dispensed to the patient, including the name and manufacturer of the bi-
6 ological product, by making an entry into an electronic system that the prescribing
7 practitioner can access electronically and that is:

8 (a) An interoperable electronic medical records system;

9 (b) An electronic prescribing technology;

10 (c) A pharmacy benefit management system; or

11 (d) A pharmacy record.

12 (3) If the pharmacy or pharmacist, or the pharmacist's designee, does not have access
13 to an electronic system described in subsection (2) of this section, the pharmacy or
14 pharmacist, or the pharmacist's designee, shall communicate not later than five business
15 days to the prescribing practitioner the specific biological product dispensed to the patient,
16 including the name and manufacturer of the biological product. The communication may be
17 by facsimile, electronic mail, telephone or another method.

18 (4) If the biological product is dispensed to a patient in an assisted living facility, clinic,
19 hospital or nursing home, an entry made to the patient's record of the specific biological
20 product dispensed to the patient, including the name and manufacturer of the biological
21 product, satisfies the communication requirements of subsections (2) and (3) of this section.

22 (5) Notwithstanding subsections (2) and (3) of this section, the pharmacy or pharmacist,
23 or the pharmacist's designee, is not required to communicate to the prescribing practitioner
24 the specific biological product dispensed to the patient if:

25 (a) The United States Food and Drug Administration has not approved an interchangea-
26 ble biological product for the prescribed biological product;

27 (b) The pharmacy or pharmacist is refilling a prescription and the pharmacy or
28 pharmacist is dispensing the same biological product that was dispensed the last time the
29 pharmacy or pharmacist filled or refilled the patient's prescription; or

30 (c) The pharmacy or pharmacist is filling a prescription for a vaccine.

31 (6) The entries described in subsections (2) and (4) of this section or the communication
32 described in subsection (3) of this section provides notice to the prescribing provider of the
33 dispensation of a biological product to a patient.

34 [(3)] (7) The State Board of Pharmacy shall, *[post and regularly update]* on a website maintained
35 by the board, **maintain a link to the current list, if available, of biological** *[a list of biosimilar]*
36 products determined by the United States Food and Drug Administration to be interchangeable.

37 (8)(a) For purposes of this section, the board shall adopt by rule definitions for the terms
38 "biological product" and "interchangeable."

39 (b) The rule defining the term "biological product" must be consistent with 42 U.S.C.
40 262(i)(1).

41 (c) The rule defining the term "interchangeable" must:

42 (A) For biological products licensed under the Public Health Service Act, describe the
43 biological products that may be substituted for other biological products as having been de-
44 termined by the United States Food and Drug Administration as meeting the standards in
45 42 U.S.C. 262(k)(4); and

1 **(B) For biological products approved by the United States Food and Drug Administration**
2 **under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq., describe the biological**
3 **products that may be substituted for other biological products as having been determined**
4 **by the United States Food and Drug Administration as therapeutically equivalent as set forth**
5 **in the latest edition or supplement of the Approved Drug Products with Therapeutic Equiv-**
6 **alence Evaluations.**

7 **SECTION 2.** ORS 689.522, as amended by section 1 of this 2016 Act, is amended to read:

8 689.522. (1) A pharmacy or pharmacist filling a prescription order for a biological product may
9 not substitute a biological product for the prescribed biological product unless:

10 (a) The substitute biological product has been determined by the United States Food and Drug
11 Administration to be interchangeable with the prescribed biological product;

12 (b) The prescribing practitioner has not designated on the prescription that substitution is pro-
13 hibited;

14 (c) The patient for whom the biological product is prescribed is informed of the substitution in
15 a manner reasonable under the circumstances; and

16 (d) The pharmacy or pharmacist retains a record of the substitution for a period of not less than
17 three years.

18 *[(2) Not later than five business days after the dispensing of a biological product, the pharmacy*
19 *or pharmacist, or the pharmacist's designee, shall communicate the specific biological product dispensed*
20 *to the patient, including the name and manufacturer of the biological product, by making an entry into*
21 *an electronic system that the prescribing practitioner can access electronically and that is:]*

22 *[(a) An interoperable electronic medical records system;]*

23 *[(b) An electronic prescribing technology;]*

24 *[(c) A pharmacy benefit management system; or]*

25 *[(d) A pharmacy record.]*

26 *[(3) If the pharmacy or pharmacist, or the pharmacist's designee, does not have access to an elec-*
27 *tronic system described in subsection (2) of this section, the pharmacy or pharmacist, or the*
28 *pharmacist's designee, shall communicate not later than five business days to the prescribing practi-*
29 *tioner the specific biological product dispensed to the patient, including the name and manufacturer of*
30 *the biological product. The communication may be by facsimile, electronic mail, telephone or another*
31 *method.]*

32 *[(4) If the biological product is dispensed to a patient in an assisted living facility, clinic, hospital*
33 *or nursing home, an entry made to the patient's record of the specific biological product dispensed to*
34 *the patient, including the name and manufacturer of the biological product, satisfies the communication*
35 *requirements of subsections (2) and (3) of this section.]*

36 *[(5) Notwithstanding subsections (2) and (3) of this section, the pharmacy or pharmacist, or the*
37 *pharmacist's designee, is not required to communicate to the prescribing practitioner the specific bi-*
38 *ological product dispensed to the patient if:]*

39 *[(a) The United States Food and Drug Administration has not approved an interchangeable bi-*
40 *ological product for the prescribed biological product;]*

41 *[(b) The pharmacy or pharmacist is refilling a prescription and the pharmacy or pharmacist is*
42 *dispensing the same biological product that was dispensed the last time the pharmacy or pharmacist*
43 *filled or refilled the patient's prescription; or]*

44 *[(c) The pharmacy or pharmacist is filling a prescription for a vaccine.]*

45 *[(6) The entries described in subsections (2) and (4) of this section or the communication described*

1 *in subsection (3) of this section provides notice to the prescribing provider of the dispensation of a bi-*
2 *ological product to a patient.]*

3 [(7)] (2) The State Board of Pharmacy shall, on a website maintained by the board, maintain a
4 link to the current list, if available, of biological products determined by the United States Food and
5 Drug Administration to be interchangeable.

6 [(8)(a)] (3)(a) For purposes of this section, the board shall adopt by rule definitions for the terms
7 “biological product” and “interchangeable.”

8 (b) The rule defining the term “biological product” must be consistent with 42 U.S.C. 262(i)(1).

9 (c) The rule defining the term “interchangeable” must:

10 (A) For biological products licensed under the Public Health Service Act, describe the biological
11 products that may be substituted for other biological products as having been determined by the
12 United States Food and Drug Administration as meeting the standards in 42 U.S.C. 262(k)(4); and

13 (B) For biological products approved by the United States Food and Drug Administration under
14 the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq., describe the biological products
15 that may be substituted for other biological products as having been determined by the United
16 States Food and Drug Administration as therapeutically equivalent as set forth in the latest edition
17 or supplement of the Approved Drug Products with Therapeutic Equivalence Evaluations.

18 **SECTION 3. The amendments to ORS 689.522 by section 2 of this 2016 Act become oper-**
19 **ative on January 2, 2022.**

20 **SECTION 4. ORS 689.522 does not prohibit an insurer or other health care payer from**
21 **requiring prior authorization or imposing other appropriate utilization controls in approving**
22 **coverage for any biological product.**

23 **SECTION 5. This 2016 Act being necessary for the immediate preservation of the public**
24 **peace, health and safety, an emergency is declared to exist, and this 2016 Act takes effect**
25 **on its passage.**

26